Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib and taxanes in HER2-negative advanced gastric cancer
NCT05171530Phase 1Unknown
- Sponsor
- Ruijin Hospital
- Start
- Jan 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lenvatinib in gastric cancer (GC), sponsored by Ruijin Hospital. Primary endpoints: Adverse events at 4 weeks and Treatment Related adverse events at 4 weeks. Status: unknown.
02
Drugs
lenvatinib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05171530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05171530.